Skip to main content
. 2019 Dec 2;9:18094. doi: 10.1038/s41598-019-54695-w

Figure 2.

Figure 2

Anti-myeloma activity of DPP8/9 inhibitor. (A) 1.0 × 105 Delta47 (rhombuses), U266 (inverted triangles), KMS-5 (squares), RPMI8226 (triangles), or MM.1 S (circles) cells were cultured with 1G244 (0–100 µM) for 72 hours. Cell number was estimated by a colorimetric assay using WST-1 reagent (n = 6). (B) 0.5 × 105 MM.1 S cells were subcutaneously inoculated into NOG mice (n = 6). Three days after the inoculation, 1G244 (30 mg/kg) was administered subcutaneously once-a-week. The tumor volume was measured every third or fourth day. (C) 0.1–0.5 × 105 CD138 + myeloma cells from patients were cultured with 1G244 (50 µM) for 24 hr (patient number 2–5) or 48 hr (patient number 1) Non-viable cells were estimated by a flow cytometric analysis using 7-AAD reagent (n = 3). (D) 1.0 × 105 MM.1 S (left panel) or KMS-5 (right panel) cells were cultured with bortezomib (20 or 40 nM) with or without 1G244 (0.5 or 5 µM) for 72 hours, respectively. Cell number was estimated by a colorimetric assay using WST-1 reagent (n = 6). The data are presented as the mean ± SD.